$0.09
Atreca is a biotechnology business based in the US. Atreca shares (BCEL) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.09 – the same closing value as a week prior. Atreca employs 90 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy Atreca stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Atreca stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BCEL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Atreca stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Atreca stock price (PINK: BCEL)
Use our graph to track the performance of BCEL stocks over time.Atreca shares at a glance
Latest market close | $0.09 |
---|---|
52-week range | $0.05 - $0.44 |
50-day moving average | $0.09 |
200-day moving average | $0.20 |
Wall St. target price | $2.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-2.50 |
Atreca price performance over time
Historical closes compared with the close of $0.09 from 2024-06-14
1 week (2024-10-11) | N/A |
---|---|
1 month (2024-09-18) | N/A |
3 months (2024-07-18) | N/A |
6 months (2024-04-22) | 5.88% |
1 year (2023-10-20) | -66.79% |
---|---|
2 years (2022-10-21) | -93.96% |
3 years (2021-10-18) | N/A |
5 years (2019-10-22) | 10.57 |
Atreca financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -51.2% |
Return on equity TTM | -182.7% |
Profit margin | 0% |
Book value | $0.27 |
Market Capitalization | $3.6 million |
TTM: trailing 12 months
Atreca share dividends
We're not expecting Atreca to pay a dividend over the next 12 months.
Have Atreca's shares ever split?
Atreca's shares were split on a 1:6 basis on 6 June 2019 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Atreca shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Atreca shares which in turn could have impacted Atreca's share price.
Atreca share price volatility
Over the last 12 months, Atreca's shares have ranged in value from as little as $0.052 up to $0.4448. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Atreca's is 1.026. This would suggest that Atreca's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Atreca overview
Atreca, Inc. , a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria.
Frequently asked questions
nullWhat percentage of Atreca is owned by insiders or institutions?
Currently 2.682% of Atreca shares are held by insiders and 8.385% by institutions. How many people work for Atreca?
Latest data suggests 90 work at Atreca. When does the fiscal year end for Atreca?
Atreca's fiscal year ends in December. Where is Atreca based?
Atreca's address is: 835 Industrial Road, South San Francisco, CA, United States, 94070 What is Atreca's ISIN number?
Atreca's international securities identification number is: US04965G1094 What is Atreca's CUSIP number?
Atreca's Committee on Uniform Securities Identification Procedures number is: 04965G109
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question